首页|期刊导航|陕西医学杂志|黄芩素调控SLC7A11/GPX4信号通路改善铁死亡促进骨髓间充质干细胞成骨分化实验研究

黄芩素调控SLC7A11/GPX4信号通路改善铁死亡促进骨髓间充质干细胞成骨分化实验研究OA

Baicalein regulating SLC7A11/GPX4 signaling pathway to improve ferroptosis and promote osteogenic differentiation of BMSCs

中文摘要英文摘要

目的:探讨黄芩素(BAI)通过调控溶质载体家族7成员11(SLC7A11)/谷胱甘肽过氧化物酶4(GPX4)信号通路抑制骨髓间充质干细胞(BMSCs)铁死亡、促进成骨分化的作用.方法:采用高糖高脂(HGHF)环境联合铁死亡诱导剂Erastin构建BMSCs铁死亡及成骨功能受损模型,并给予BAI及铁死亡抑制剂Ferrostatin-1(Fer-1)干预.实验分为五组:①对照组(正常培养条件);②模型组(HGHF环境);③铁死亡诱导剂组(HGHF+300 μmol/L Erastin);④模型+BAI 组(HGHF+20 μmol/L BAI);⑤模型+铁死亡抑制剂组(HGHF+10 μmol/L Fer-1).采用CCK-8法检测细胞活力;采用透射电镜观察线粒体超微结构变化;应用二氯荧光素(DCFH-DA)探针及相关试剂盒检测活性氧(ROS)、丙二醛(MDA)、谷胱甘肽(GSH)水平;采用茜素红S染色评价矿化结节形成;采用Western blot法检测SLC7A11、GPX4、酰基辅酶A合成酶长链家族成员4(ACSL4)、铁蛋白重链1(FTH1)及成骨相关蛋白Runt相关转录因子2(RUNX2)、Ⅰ型胶原α1链(COL1A1)、骨钙素(OCN)的表达水平.结果:与对照组比较,模型组和铁死亡诱导剂组的BMSCs细胞活力显著降低,线粒体结构出现明显萎缩、膜破裂和嵴减少(均P<0.05).与模型组和铁死亡诱导剂组比较,模型+BAI组细胞活力明显提高,线粒体结构得到显著改善,细胞内ROS、MDA水平显著降低,GSH水平显著升高(均P<0.05).同时,BAI干预显著上调SLC7A11、GPX4、FTH1、RUNX2、COL1A1和OCN的蛋白表达,显著下调ACSL4的表达,促进矿化结节的形成(均P<0.05).这些结果表明,BAI能够有效改善BMSCs的活性和成骨分化能力,其效果与模型+铁死亡抑制剂组相似.结论:BAI可通过激活SLC7A11/GPX4信号通路抑制BMSCs铁死亡,减轻氧化应激损伤,从而恢复其成骨分化能力.

Objective:To investigate the role of Baicalein(BAI)in inhibiting ferroptosis in bone marrow mesen-chymal stem cells(BMSCs)and promoting osteogenic differentiation through regulating the solute carrier family 7 member 11(SLC7A11)/glutathione peroxidase 4(GPX4)signaling pathway.Methods:A BMSCs ferroptosis and os-teogenic dysfunction model was established by using a high-fat,high-glucose(HGHF)environment combined with the ferroptosis inducer Erastin,followed by intervention with BAI and ferroptosis inhibitor Ferrostatin-1(Fer-1).The experiment was divided into five groups:①Control group(normal culture conditions);② Model group(HGHF environment);③ Ferroptosis inducer group(HGHF+300 μmol/L Erastin);④ Model+BAI group(HGHF+20 μmol/L BAI);⑤ Model+ferroptosis inhibitor group(HGHF+10 μmol/L Fer-1).Cell viability was measured using the CCK-8 assay.Mitochondrial ultrastructure was observed by transmission electron microscopy.Reactive oxy-gen species(ROS),malondialdehyde(MDA),and glutathione(GSH)levels were assessed using DCFH-DA probes and related kits.Mineralized nodule formation was evaluated by alizarin red S staining;and the expression levels of SLC7A11,GPX4,acyl-CoA synthetase long-chain family member 4(ACSL4),ferritin heavy chain 1(FTH1),and os-teogenic markers runt-related transcription factor 2(RUNX2),collagen type Ⅰ alpha 1 chain(COL1A1),and osteo-calcin(OCN)were measured by Western blot.Results:Compared with the control group,the BMSCs cell viability in the model group and ferroptosis inducer group was significantly decreased,with obvious mitochondrial shrinkage,membrane rupture,and cristae reduction(all P<0.05).Compared with the model group and the ferroptosis inducer group,the cell viability of the model+BAI group was significantly enhanced,the mitochondrial structure was signifi-cantly improved,the intracellular ROS and MDA levels were significantly decreased,and the GSH level was signifi-cantly increased(all P<0.05).Meanwhile,BAI intervention significantly upregulated the protein expressions of SLC7A11,GPX4,FTH1,RUNX2,COL1A1 and OCN,significantly downregulated the expression of ACSL4,and promoted the formation of mineralized nodules(all P<0.05).These results indicated that BAI could effectively en-hance the activity and osteogenic differentiation ability of BMSCs,and its effect was similar to that of the model+fer-roptosis inhibitor group.Conclusion:BAI can inhibit ferroptosis in BMSCs and alleviate oxidative stress injury by acti-vating the SLC7A11/GPX4 signaling pathway,thereby restoring their osteogenic differentiation ability.

续斌;杨燕;高健;柴浩;王国胜

新疆医科大学第六附属医院创伤二科,新疆乌鲁木齐83000新疆医科大学第六附属医院创伤二科,新疆乌鲁木齐83000新疆医科大学第六附属医院创伤二科,新疆乌鲁木齐83000新疆医科大学第六附属医院创伤二科,新疆乌鲁木齐83000新疆医科大学第六附属医院创伤二科,新疆乌鲁木齐83000

医药卫生

骨质疏松骨髓间充质干细胞黄芩素铁死亡溶质载体家族7成员11/谷胱甘肽过氧化物酶4通路成骨分化

OsteoporosisBone marrow mesenchymal stem cellsBaicaleinFerroptosisSLC7A11/GPX4 path-wayOsteogenic differentiation

《陕西医学杂志》 2026 (6)

761-768,8

新疆维吾尔自治区自然科学基金资助项目(2019D01C246)新疆维吾尔自治区"天山英才"医药卫生高层次人才培养计划(TSYC202301B107)

10.3969/j.issn.1000-7377.2026.06.007

评论